Investor Relations

Stock Information

Symbol

Nasdaq: VTGN

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medications for anxiety, depression and other central nervous system, or “CNS,” diseases and disorders where current treatments are inadequate to address high unmet need. Our CNS portfolio includes three differentiated CNS drug candidates, PH94B, PH10 and AV-101, each with a novel mechanism of action, an exceptional safety profile, and therapeutic potential for multiple indications.

Contact Information

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate Development
(650) 577-3606
markmcp@vistagen.com

Investor Relations
KCSA Strategic Communications
Valter Pinto / Allison Soss
(212) 896-1254 / (212) 896-1267
VistaGen@KCSA.com

Public Relations
KCSA Strategic Communications
Caitlin Kasunich / Lisa Lipson
(212) 896-1241 / (508) 843-6428
VistaGen@KCSA.com

Transfer Agent
Computershare, Inc.
P.O. BOX 30170
College Station, TX 77842
(800) 368-5948
www-us.computershare.com